Trav8-4: A Potential Drug Target for Cancer and Other Diseases

Target Name: TRAV8-4

NCBI ID: G28682

TRAV8-4

Other Name(s): TRAV84 | T cell receptor alpha variable 8-4 | TCRAV8S4 | TCRAV1S2

Trav8-4: A Potential Drug Target for Cancer and Other Diseases

Trav8-4, also known as TRAV84, is a protein that is expressed in various tissues of the body, including the brain, pancreas, and heart. Its function is not well understood, but it is believed to play a role in the development and progression of several diseases, including cancer.

One of the most promising aspects of Trav8-4 is its potential as a drug target. Researchers have identified several potential binding sites on Trav8-4 that they believe could be targeted by small molecules. These sites are located in the protein's extracellular domain, which consists of the regions of the protein that interact with other molecules in the body.

While more research is needed to fully understand the potential of Trav8-4 as a drug target, studies have shown that it can interact with several different molecules, including G protein-coupled receptors (GPCRs), which are a family of transmembrane proteins that play a role in signaling throughout the body.

GPCRs are involved in many different processes in the body, including sensory perception, neurotransmitter signaling, and cellular signaling. They are also often involved in diseases such as diabetes, hypertension, and heart failure, making them an attractive target for drug development.

Trav8-4 has been shown to interact with several different GPCRs, including the尾2-adrenergic receptor (尾2AR), which is involved in the regulation of heart rate and blood pressure.尾2AR is a common target for many drugs used to treat cardiovascular disease, including beta-blockers, which are used to slow the heart rate and reduce blood pressure.

Another potential target for Trav8-4 is the PDGF receptor (PDGF), which is involved in cell signaling and growth. Trav8-4 has been shown to interact with the PDGF receptor, which suggests that it may be a useful target for drugs that are used to treat diseases such as cancer.

In addition to its potential as a drug target, Trav8-4 has also been shown to play a role in the development and progression of several diseases. For example, studies have shown that Trav8-4 is overexpressed in several types of cancer, including breast, lung, and colorectal cancer. This suggests that Trav8-4 may be a useful biomarker for these diseases and may help doctors to diagnose and treat them more effectively.

Overall, Trav8-4 is a protein that has the potential to be a drug target for several diseases, including cancer. While more research is needed to fully understand its function and to develop effective treatments, its potential as a drug target is an exciting area of research that could lead to new treatments for a variety of diseases.

Protein Name: T Cell Receptor Alpha Variable 8-4

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV8-4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV8-4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets